SOUTH SAN FRANCISCO, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ("ALX Oncology"; Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives, today announced its participation in the 44th Annual J.P. Morgan Healthcare Conference in San Francisco. Chief Executive Officer Jason Lettmann and Chief Medical Officer Barbara Klencke will deliver a corporate presentation on Thursday, January 15, 2026, at ...

Key Takeaways Krystal Biotech shares have climbed 57.2% in a year, far outperforming the biotech industry and sector.Vyjuvek uptake remains strong after FDA label expansion and approvals in the U.S., Japan and Europe.KRYS is advancing a broad pipeline across respiratory, ophthalmology, oncology, dermatology and aesthetics.Shares of Krystal Biotech (KRYS) have surged 57.2% in a year compared with the industry’s growth of 17.1%. The stock has also outperformed the industry and the sector in this time frame.Th ...

Company Overview - Proactive provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2] - The news team operates from key finance and investing hubs including London, New York, Toronto, Vancouver, Sydney, and Perth [2] Market Focus - Proactive specializes in medium and small-cap markets while also covering blue-chip companies, commodities, and broader investment stories [3] - The content includes insights across various sectors such as biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto, and emerging digital and EV technologies [3] Technology Utilization - Proactive is a forward-looking company that adopts technology enthusiastically to enhance workflows [4] - The company utilizes automation and software tools, including generative AI, while ensuring all content is edited and authored by humans [5]

Alzheimer's Clinical and Biomarker Outcomes Expected in Q1 2026 CAMBRIDGE, Mass., Jan. 8, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, today announced that Prof. Steven E. Arnold, a world-renowned Alzheimer's disease expert and Professor of Neurology at Harvard Medical School, has joined the Company's Scientific Advisory Board. Prof. Arnold brings decades of exp ...

As part of the branding process, Polyrizon conducted comprehensive trademark screening across the U.S. and European markets Raanana, Israel, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a pre-clinical-stage biotechnology company developing intranasal protective solutions, today announced that it has completed the branding process for its PL-14 allergy blocker, which will be marketed under the brand name NASARIX™. NASARIX™ is based on Polyriz ...

1H 2026 Catalyst Stack Anticipated to Validate Scalable, Off-the-Shelf CAR T in Oncology and Autoimmune Disease Interim Futility Analysis of MRD Clearance from the Pivotal Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line (1L) Consolidation Large B-Cell Lymphoma (LBCL) Planned for Early Q2 2026Initial Proof-of-Concept for ALLO-329, the Dual CD19/CD70 AlloCAR T Leveraging the Dagger® Technology to Reduce or Eliminate Lymphodepletion in the Treatment of Autoimmune Diseases, Slated ...

PHILADELPHIA, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases and cancer, today announced it has entered into a securities purchase agreement for a private placement for initial gross proceeds of approximately $135 million to the Company, before placement agent fees and offering expenses. The financing is being led by new investor TCGX, and includes p ...

Core Insights - Humacyte, Inc. announced results from a five-year analysis of hospital charges and healthcare costs related to extremity arterial injuries, highlighting the financial burden of preventable complications [1][2][5] Group 1: Financial Impact of Complications - Average hospital charge for extremity arterial injury repair was $316,600 per patient, with preventable complications like amputation and conduit infection increasing charges by approximately $493,000 and $590,000 respectively [1][3] - The average reimbursed cost for extremity arterial injury repair was significantly lower at $75,947, indicating a disparity between hospital charges and reimbursement [3] - Vascular graft infection and amputation resulted in additional hospital charges of $589,921 and $492,986 respectively, with average reimbursements of $84,598 and $116,611 [3] Group 2: Symvess Product Overview - Humacyte's Symvess is an acellular tissue engineered vessel designed for urgent revascularization in extremity arterial injuries when autologous vein grafts are not feasible [4][6] - Symvess has demonstrated low rates of infection and high limb salvage rates compared to historical controls, with infection rates one-ninth and amputation rates one-fifth of those seen with synthetic grafts [4][5] - The product is designed to be available off-the-shelf, which can save critical surgical time in emergency situations [5] Group 3: Clinical and Market Context - The analysis included data from 964 adult patients treated for extremity arterial injuries from 2018 to 2023, prior to the FDA approval of Symvess [2] - The patient cohort had an average age of 36.5 years, with 26% treated using conduits other than autologous vein, indicating a significant market for alternative solutions like Symvess [3][5] - Recent positive results from the V005 Phase 2/3 study of Symvess provide the first long-term data for traumatic arterial repair using a biologic conduit [5]

At 7:25 a.m. ET on Thursday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening bell.For active traders, premarket trading offers a head start in spotting potential breakouts, reversals, or sharp price swings. These early moves often indicate where momentum may carry into the regular session, making premarket analysis a key part of the trading day.In the Green - Premarket GainersThe following stocks are trading hig ...

About this content About Ian Lyall Ian Lyall, a seasoned journalist and editor, brings over three decades of experience to his role as Managing Editor at Proactive. Overseeing Proactive's editorial and broadcast operations across six offices on three continents, Ian is responsible for quality control, editorial policy, and content production. He directs the creation of 50,000 pieces of real-time news, feature articles, and filmed interviews annually. Prior to Proactive, Ian helped lead the business outpu ...